Eil Therapeutics, Inc.

The Scripps Research Institute

Als Therapy Development Institute

Expansion Therapeutics, Inc.

Alexei Pushechnikov

Alexandre Vasilievich Ivachtchenko

Ruben Abagyan

Vladislav Zenonovich Parchinsky

Volodymyr Kysil

Polo Chun-Hung Lam

Nikolay Savchuk

Andrew Orry

Joseph P Vacca

Matthew D Disney

Timothy Allen Blizzard

Andy Jennings

Suzanne Rzuczek

Matvey Lukashev

Kyle Denton

John Ndungu

Peter Demin

The present disclosure relates to copper complexes, pharmaceutical compositions comprising these complexes, chemical processes for preparing these complexes, and their use in the treatment of neurodegenerative disease, e.g., amyotrophic lateral sclerosis (ALS).

Copper complexes for treatment of neurodegenerative disorders

The present invention is generally directed to inhibitors of BCL-2 proteins useful in the treatment of diseases and disorders modulated by said enzyme and having the Formula (I):

Compounds having ((3-nitrophenyl)sulfonyl)acetamide as BCL-2 inhibitors

Compounds having tetrahydroindolizine-1-carboxamide as BCL-2 inhibitors

Provided herein are compounds and methods for modulating abnormal repeat expansions of gene sequences. More particularly, provided are inhibitors of RNA and the uses of such inhibitors in regulating nucleotide repeat expansions, e.g., to treat Myotonic Dystrophy Type 1 (DM1), Myotonic Dystrophy Type 2 (DM2), Fuchs dystrophy, Huntington Disease, Amyotrophic Lateral Sclerosis, or Frontotemporal Dementia.

Bis-benzimidazole compounds and methods of using the same

Growing community of inventors

San Diego, CA, United States of America

Alexei Pushechnikov